Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone44-20-7401-7646
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.90 billion
Profitability
Miscellaneous
Employees16,377
Next Earnings DateN/A
OptionableOptionable
Smith & Nephew (NYSE:SNN) Frequently Asked Questions
What is Smith & Nephew's stock symbol?
Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."
How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?
Smith & Nephew declared a semiannual dividend on Friday, February 15th. Investors of record on Friday, April 5th will be paid a dividend of $0.44 per share on Wednesday, May 8th. This represents a yield of 2.31%. The ex-dividend date is Thursday, April 4th. This is an increase from Smith & Nephew's previous semiannual dividend of $0.25. View Smith & Nephew's Dividend History.
How were Smith & Nephew's earnings last quarter?
Smith & Nephew plc (NYSE:SNN) posted its quarterly earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.59. View Smith & Nephew's Earnings History.
What price target have analysts set for SNN?
7 equities research analysts have issued 12-month target prices for Smith & Nephew's stock. Their predictions range from $6.00 to $6.00. On average, they anticipate Smith & Nephew's share price to reach $6.00 in the next twelve months. This suggests that the stock has a possible downside of 87.1%. View Analyst Price Targets for Smith & Nephew.
What is the consensus analysts' recommendation for Smith & Nephew?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Smith & Nephew.
Has Smith & Nephew been receiving favorable news coverage?
Media headlines about SNN stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Smith & Nephew earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for Smith & Nephew.
Who are some of Smith & Nephew's key competitors?
Some companies that are related to Smith & Nephew include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Align Technology (ALGN), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX) and Invacare (IVC).
What other stocks do shareholders of Smith & Nephew own?
Who are Smith & Nephew's key executives?
Smith & Nephew's management team includes the folowing people:
- Mr. Namal Nawana, CEO & Exec. Director (Age 48)
- Mr. Graham Timothy Baker, CFO & Exec. Director (Age 51)
- Mr. Mark Gladwell, Pres of Global Operations (Age 44)
- Ms. Catheryn O'Rourke, Chief Legal & Compliance Officer (Age 46)
- Mr. Joe Metzger, Sr. VP of Marketing Services & Communications
Who are Smith & Nephew's major shareholders?
Smith & Nephew's stock is owned by many different of institutional and retail investors. Top institutional investors include Fiduciary Management Inc. WI (1.93%), Cambiar Investors LLC (1.14%), Iridian Asset Management LLC CT (0.60%), Nuance Investments LLC (0.35%), Bank of America Corp DE (0.30%) and Foresters Investment Management Company Inc. (0.20%).
Which major investors are selling Smith & Nephew stock?
SNN stock was sold by a variety of institutional investors in the last quarter, including Cambiar Investors LLC, Morgan Stanley, US Bancorp DE, Bank of America Corp DE, Citadel Advisors LLC, Dalton Greiner Hartman Maher & Co., JPMorgan Chase & Co. and Sio Capital Management LLC.
Which major investors are buying Smith & Nephew stock?
SNN stock was purchased by a variety of institutional investors in the last quarter, including Prio Wealth Limited Partnership, Amundi Pioneer Asset Management Inc., Nuance Investments LLC, Iridian Asset Management LLC CT, Jane Street Group LLC, Fiduciary Management Inc. WI, Assetmark Inc. and Reilly Financial Advisors LLC.
How do I buy shares of Smith & Nephew?
Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Smith & Nephew's stock price today?
One share of SNN stock can currently be purchased for approximately $46.62.
How big of a company is Smith & Nephew?
Smith & Nephew has a market capitalization of $20.39 billion and generates $4.90 billion in revenue each year. The medical equipment provider earns $663 million in net income (profit) each year or $2.02 on an earnings per share basis. Smith & Nephew employs 16,377 workers across the globe.View Additional Information About Smith & Nephew.
What is Smith & Nephew's official website?
How can I contact Smith & Nephew?
Smith & Nephew's mailing address is 15 ADAM STREET, LONDON X0, WC2N 6LA. The medical equipment provider can be reached via phone at 44-20-7401-7646 or via email at [email protected]
MarketBeat Community Rating for Smith & Nephew (NYSE SNN)
MarketBeat's community ratings are surveys of what our community members think about Smith & Nephew and other stocks. Vote "Outperform" if you believe SNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNN will underperform the S&P 500 over the long term. You may vote once every thirty days.
